COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations

R Grainger, AHJ Kim, R Conway, J Yazdany… - Nature Reviews …, 2022 - nature.com
The COVID-19 pandemic has brought challenges for people with rheumatic disease in
addition to those faced by the general population, including concerns about higher risks of …

Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review

S Galmiche, LBL Nguyen, E Tartour… - Clinical Microbiology …, 2022 - Elsevier
Background Available data show that COVID-19 vaccines may be less effective in
immunocompromised populations, who are at increased risk of severe COVID-19 …

Effect of immunosuppression on the immunogenicity of mRNA vaccines to SARS-CoV-2: a prospective cohort study

P Deepak, W Kim, MA Paley, M Yang… - Annals of internal …, 2021 - acpjournals.org
Background: Patients with chronic inflammatory disease (CID) treated with
immunosuppressive medications have increased risk for severe COVID-19. Although mRNA …

Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: systematic review and meta-analysis

A Jena, S Mishra, P Deepak, P Kumar-M, A Sharma… - Autoimmunity …, 2022 - Elsevier
Objectives The treatment for COVID-19 often utilizes immune-modulating drugs. These
drugs are also used in immune mediated inflammatory diseases (IMIDs). We performed a …

[HTML][HTML] Effectiveness of SARS-CoV-2 mRNA vaccines for preventing Covid-19 hospitalizations in the United States

MW Tenforde, MM Patel, AA Ginde, DJ Douin… - MedRxiv, 2021 - ncbi.nlm.nih.gov
Background: As SARS-CoV-2 vaccination coverage increases in the United States (US),
there is a need to understand the real-world effectiveness against severe Covid-19 and …

Evaluation of immune response and disease status in systemic lupus erythematosus patients following SARS–CoV‐2 vaccination

PM Izmirly, MY Kim, M Samanovic… - Arthritis & …, 2022 - Wiley Online Library
Objective To evaluate seroreactivity and disease flares after COVID‐19 vaccination in a
multiethnic/multiracial cohort of patients with systemic lupus erythematosus (SLE). Methods …

Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients' subgroups

C Ferri, F Ursini, L Gragnani, V Raimondo… - Journal of …, 2021 - Elsevier
Autoimmune systemic diseases (ASD) may show impaired immunogenicity to COVID-19
vaccines. Our prospective observational multicenter study aimed to evaluate the …

Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions …

A Abhishek, RJ Boyton, N Peckham… - The Lancet …, 2022 - thelancet.com
Background Immunosuppressive treatments inhibit vaccine-induced immunity against SARS-
CoV-2. We evaluated whether a 2-week interruption of methotrexate treatment immediately …

Risk and prognosis of SARS-CoV-2 infection and vaccination against SARS-CoV-2 in rheumatic and musculoskeletal diseases: a systematic literature review to inform …

FPB Kroon, A Najm, A Alunno, JW Schoones… - Annals of the …, 2022 - ard.bmj.com
Objectives Perform a systematic literature review (SLR) on risk and prognosis of SARS-CoV-
2 infection and vaccination against SARS-CoV-2 in patients with rheumatic and …

COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses

F Fagni, D Simon, K Tascilar, V Schoenau… - The Lancet …, 2021 - thelancet.com
At the beginning of the COVID-19 pandemic, patients with immune-mediated inflammatory
diseases were considered to be at high risk for SARS-CoV-2 infection and the development …